Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Hepatocellular 19 Carcinoma, Renal Cell 13 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Endometrial Neoplasms 6 Neoplasms 4 Biliary Tract Neoplasms 4 Neuroendocrine Tumors 3 Melanoma 3 Liver Neoplasms 3 Vulvar Neoplasms 2 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 von Hippel-Lindau Disease 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Penile Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Lung Neoplasms 1 Kidney Neoplasms 1 Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1

Interventions

Cyclophosphamide 15 fludarabine 12 Mycophenolic Acid 10 Standard of Care 9 Whole-Body Irradiation 7 Tacrolimus 7 venetoclax 6 Specimen Handling 6 Sirolimus 6 Practice Guidelines as Topic 6 trametinib 5 Melphalan 5 fludarabine phosphate 4 Mesna 4 Magnetic Resonance Spectroscopy 4 Filgrastim 4 Biopsy 4 Behavior Therapy 4 Azacitidine 4 Thiotepa 3 Peripheral Blood Stem Cell Transplantation 3 GSK2636771 3 Educational Status 3 Crizotinib 3 Busulfan 3 thymoglobulin 2 talquetamab 2 ruxolitinib 2 palbociclib 2 osimertinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hematologic Neoplasms × lenvatinib × 90 days × Clear all

NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡